

Twenty Five years of Experience on Stem Cell Transplantation in Iran



Ardeshir Ghavamzadeh M.D

Nov , 17th, 2015
Tehran, Iran


**Hematology- Oncology and Stem Cell
Transplantation Research Center
Tehran University of Medical Science**




HEMATOLOGY
ONCOLOGY
&
B.M.T
RESEARCH
CENTER

مرکز تحقیقاتی
و
تحقیقاتی مرکز سرطان

مرکز تحقیقاتی و تحقیقاتی مرکز سرطان



Hsct Centers in Iran




HSCT Centers in Iran

Number of HSCT
till 13,Sep, 2015


HORC-SCT, Shariati Hospital (Tehran)	5235
Namazi Hospital (Shiraz)	1018
Imam Khomeini Hospital (Tehran)	360
Afzali pour Hospital(Kerman)	141
Amir kola Hospital (Babol)	74
Imam Khomeini Hospital (Urmia)	24
Mahak Hospital (Tehran)	117
Montaserieh Hospital (Mashhad)	31
Shafa Hospital (Ahvaz)	6
Taleghani Hospital (Tehran)	?
Total	7006





Location of Centers participating in the CIBMTR 2011



Participating Countries for Activity Survey





Stem Cell Transplantation Indication

- **1- Hemoglobinopathies**
- 2- Anemias (Severe Aplastic Anemia, Fanconi Anemia,...)**
- 3- Disorders of Immune System (LAD, SCID, WAS, Kostmann, Job, Griscelli,...)**
- 4- Metabolic and Storage Disease (Hurler, Gaucher,...)**
- 5- Hematological Malignancies (AML , ALL , CML , MM , Lymphoma,...)**
- 6- Myelofibrosis**
- 7- Autoimmune diseases (RA, SLE, MS, Scleroderma,...)**

Stem Cell Transplantation Indication

•8- Solid tumors: Breast cancer, Ovary, Testis, Ewing Sarcoma , Osteosarcoma, Neuroblastoma

9- Cell Therapy:

Post Infarction (CABG, Angioplasty)

Multiple Sclerosis

Cirrhosis

Avascular Necrosis of Femoral Head


Diabetes Mellitus II

GvHD treatment

Systematic Lupus Erythematosus

Thalassemia

HSCT 1991- 1st Nov. 2015



Stem Cell Transplantation Report (March 1991-Nov. 2015)

Leukemias		2335
Acute Myelogenous Leukemia		1296
Acute Lymphoblastic Leukemia		761
Chronic Myelogenous Leukemia		258
Chronic Lymphoblastic Leukemia		7
Other Leukemias		13

Lymphomas		685
Hodgkin Disease		363
Non –Hodgkin Lymphoma		322

Inherited Abnormalities of RBC		911
Thalassemia		742
Fanconi Anemia		148
Diamond- Blackfan Anemia		11
Sickle- Cell Thalassemia		5
Sickle Cell Disease		5

MDS / MPS		96
Myelodysplastic Disorders		80
Myeloproliferative Disorders		16

Severe Aplastic Anemia		266
Aplastic Anemia		253
PNH		13

Plasma Cell Disorders		700
Multiple Myeloma		671
Amyloidosis		10
Plasma Cell Leukemia		8
Solitary Plasmacytoma		9
Multiple Plasmacytoma		2

Autoimmune Diseases		5
Systemic Sclerosis (Scleroderma)		4
Multiple Sclerosis		1

Stem Cell Transplantation Report (March 1991-Nov 2015)

Disorders of Immune System		73
LADs		24
Wiskott- Aldrich Syndrome		11
SCID		18
Chediak – Higashi Syndrome		9
Griscelli Syndrome		7
Hyper IgE Syndrome		2
Idiopathic CD4 Lymphocytopenia		1
Congenital Neutropenia (Kostmann)		1

Histiocytic Disorders		10
Familial Erythrophagocytic Lymphohistiocytosis (FELH)		8
Histiocytosis- X		2

Inherited Disorders of Metabolism		46
Osteopetrosis		27
Hurler Syndrome		5
Mucopolysaccharidosis (Mucopolysaccharidosis) (Niemann- Pick Disease)		7
Maroteaux- Lamy Syndrome		3
Mitochondrial Neurogastrointestinal Encephalomyopathy		1
Metachromatic Leukodystrophy		2
Adrenoleukodystrophy		1

Solid Tumors		109
Neuroblastoma		41
Breast Cancer		13
Ewing Sarcoma		11
Testicular Tumors		9
Germ Cell Tumors		7
Wilm's Tumor		5
Medulloblastoma		6
Ovarian Tumors		3
Renal Cell Carcinoma		2
Bone Sarcoma		2
Soft Tissue Sarcoma of Kidney		3
Rhabdomyosarcoma		2
Neuroendocrine Tumor		1
PNET		1
Clear cell sarcoma of Kidney		1
Pancreatoblastoma		1
Nasopharyngeal Carcinoma		1

Patients characteristics

Total no of our patients	5373
HSCT	5237
Retransplantation	71
Cell therapy	239
Allogeneic	3595
HLA- identical sibling	3112
HLA- matched other relatives	215
mismatched sibling/other related	139
unrelated	125
haploidentical	80
Autologous	1623
Syngeneic	19

Sources of HSCT



Sources	No
PB	4504
PB+ Mesenchymal	66
BM	539
BM+ Mesenchymal	38
CB	65
BM + PB	19
BM + PB+ Mesenchymal	3

Cell therapies

Diseases	No
Thalassemia Major	103
Post MI	52
Cirrhosis	30
Diabetes Mellitus	21
Head of femur necrosis	13
Multiple sclerosis	11
GvHD treatment	9
Total	239

AML

Total	1296
Allogeneic	1031
Autologous	260
Syngeneic	5
Alive	800 (63.8 %)




AML


DFS

OS

AML Free Survival



AML Overall Survival




p < 0.0037

P=0.0002

ALL


Total	761
Allogeneic	725
Autologous	26
Syngeneic	10
Alive	414 (54.4%)



ALL

DFS


ALL Free Survival



p=0.3482

OS


ALL Overall Survival



p=0.0438


CML

Total Allogeneic	258
Peripheral Blood	228
Bone Marrow	30
Alive	175(67.8%)



Non- Hodgkin Lymphoma

Total	322
Autologous	268
Allogeneic	53
Syngeneic	1
Alive	244 (75.7%)




Non- Hodgkin Lymphoma


DFS

OS

NHL Free Survival



NHL Overall Survival




P=0.1143

p= 0.1023

Hodgkin Disease

Total	363
Autologous	352
Allogeneic	11
Alive	320 (88.1%)




Hodgkin Disease


DFS

OS

HD Free Survival



HD Overall Survival




P=0.0053

p= 0.72

Aplastic Anemia & PNH

Total Allogeneic AA	253
Peripheral Blood	193
Bone Marrow	55
PB + BM	3
Cord Blood	2
Alive	198 (78.2%)

Total Allogeneic PNH	13
Alive	10 (77%)




Aplastic Anemia & PNH

PB vs. BM


DFS

OS

Aplastic Anemia Free Survival



Aplastic Anemia Overall Survival




p= 0.119

p= 0.707

Fanconi Anemia

Total	148
Peripheral Blood	99
Bone Marrow	42
Cord Blood	6
PB + BM	1
Alive	102 (68.9%)




Fanconi Anemia

DFS


OS

Fanconi Anemia Free Survival



p= 0.9814

Fanconi Anemia Overall Survival




p= 0.9075

Plasma cell disorders

Total	700
Multiple Myeloma	671
Amyloidosis	10
Plasmacytoma	11
Plasma cell leukemia (PCL)	8

Multiple Myeloma

Total	671
Autologous	583
Allogeneic	88
Alive	510 (83%)




Multiple Myeloma


DFS

OS

MM Free Survival



MM Overall Survival





p= 0.9402

p= 0.6440

Myelodysplasia (MDS)

Total	80
PB	77
BM	2
CB	1
Alive	52 (65%)



Solid Tumors

Total	113
Autologous	105
Allogeneic	8
Alive	79 (69.9%)


Solid Tumors

Total		113	
Breast Cancer	13	Pancreatoblastoma	1
Testicular Tumors	9	Rhabdomyosarcoma	2
Ewing Sarcoma	11	Wilm s Tumor	6
Germ Cell Tumors	7	Head& Neak Tumors	1
Neuroblastoma	44	Bone Sarcoma	2
Medulloblastoma	6	NeroEndocrine tumor	1
Ovarian Tumors	3	Extea-osseous include PNET	1
Renal Cell Carcinoma	2	CNS tumors(including CNS PNET)	1
Clear Cell Sarcoma of Kidney	1	Soft Tissue Sarcoma	2

Major Beta- Thalassemia

Total	724
PB	385
BM	220
CB	13
PB+ Mesenchymal	64
BM + Mesenchymal	36
PB + BM + Mesenchymal	3
PB + BM	3
Classification	
Class I	175
Class II	283
Class III	265


Thalassemia	724
Sickle cell thalassemia	5
Sickle cell disease	5




Major Beta- Thalassemia

DFS & OS

Thalassemia Free Survival



Thalassemia Overall Survival




Major Beta- Thalassemia

BM vs. PB

DFS

OS

Thalassemia Free Survival



p= 0.6298

Thalassemia Overall Survival





p= 0.7896

Major Beta- Thalassemia

BM Vs. PB Regarding GvHD

DFS

OS




BM without cGvHD: 5 Years OS= 76.38%
BM with cGvHD: 5 Years OS= 87.5%
PB without cGvHD: 5 Years OS= 73.64%
PB with cGvHD: 5 Years OS= 80.13%

BM without cGvHD: 5 Years DFS= 71.48%
BM with cGvHD: 5 Years DFS= 87.5%
PB without cGvHD: 5 Years DFS= 68.95%
PB with cGvHD: 5 Years DFS= 80.13%

Outpatients ward

First transplantation was done in Dec 2005
All of the were Autologous PB

Diseases	No
Multiple Myeloma	99
Hodgkin	24
NHL	10
AML	6
Total	139




Relapse	84 (58%)
Alive	96 (65.75%)

Causes of death	No
Relapse	41
infection	4
Other	5


Multiple Myeloma Outpatients

DFS & OS

MM Free Survival



MM Overall Survival



Haploidentical

Start :2007

to May,2, 2015: 80 (patients)

Alive: 67/5% 54


Mortality: 32.4% 26

Studies in Progress

- ❖ Unrelated transplantation
- ❖ Haploidentical HSCT
- ❖ Cord Blood & double Cord Blood HSCT
- ❖ Use of Mesenchymal stem cells



Hematopoietic stem cell




Cord blood Bank



- First Iranian public cord blood bank
- Established at 2002
- Gathering cord blood cells from multiple Gynecology/ Obstetric centers
- First CB transplantation was done at 1998
- 66 Cord blood transplantations done
- Development of bank and new methods of storage and tests
- **3254 stored (3224 HLA-typed)**

HLA- Bank



- Iranian stem cell donor program
(بانک اهدا کنندگان سلولهای بنیادی) -
- First in Middle - East
- At 1999 joined to BMDW and WMDA
- Search for matched donors all over the world
- It is growing day to day with increasing number of volunteers
- **7589 HLA-typed**
- **21807 direct registered**

Acknowledgment:

Prof.Mohammad. Jahani
Prof. Kamran .Alimoghaddam
Associate Prof. Amir Ali Hamidieh
Dr.Babak.Bahar
Dr. Seyed Asadollah .Mousavi
Dr.Mohammad. vaezi
Dr.Hossein.Kamranzadeh
Dr.Maryam.Behfar
Dr. Mohammadreza .Ostadali
Dr.Marjan .Yaghmaei
Dr.Mohsen .Nikbakht
Dr. Sharbanoo . Rostami
Dr.Bahram . Chardovali
Dr.Amir. kasaeian
Mrs.Ashraf Sadat. Mosavi
Mrs.Zahra . Shahriari
Mrs.Simindokht . Basirpanah
Mrs.Ashraf. Hosseini
Mrs. Soheila . Khalilvandi
Mrs.Tahereh. Mirfallah

HEMATOLOGY
ONCOLOGY
&
B.M.T
RESEARCH
CENTER

پیش قدمی در تشخیص و درمان سرطان خون
با استفاده از روش‌های نوین (CI-MTR) در سال 2012 در بیمارستان
بزرگ ولی شریعتی مشهد



18th anniversary of stem cell transplantation in Iran- 2007

